GEO Heads Into Earnings With Shorts Steady and Wikipedia Interest Spiking

GEO heads into its November 5 earnings release carrying a stock that has cooled sharply from its highs, shorts that are neither retreating nor building aggressively, and a notable spike in retail attention that adds an unusual wrinkle to the setup.

The stock closed at $28.52 on October 30, down roughly 8% over the past month despite a 4.2% bounce this week. That monthly decline matters as context: GEO traded close to its 52-week high earlier in the year on federal detention capacity optimism, and the recent pullback has brought it back to a level that looks more like a re-rating than a short-driven breakdown. Short interest, at 7.2% of free float, is real but not extreme, and has drifted around a narrow band for the past six weeks, oscillating between roughly 9.4 million and 10.7 million shares without establishing a clear directional trend. The week's 1.9% increase in borrowed shares is modest. The borrow market confirms no particular urgency among short sellers: cost to borrow runs at just 0.42%, a low-cost loan by any measure, and availability is vast, with more than 22 times the current short interest still sitting unlent in the lending pool. Availability actually expanded 9% on the week, moving further away from any tightness. This is not the setup of a name under serious short pressure.

Options positioning has edged more cautious ahead of the print. The put/call ratio moved to 0.29, above its 20-day average of 0.25 and running at about 1.2 standard deviations above that mean. That is still well below the 52-week high of 0.34, so the skew is modest rather than alarmed. The direction of travel, though, is clear: the PCR has climbed steadily over the past two weeks from a low around 0.20 in early October, meaning options traders have progressively added more downside protection as the earnings date approached. That shift in tone, combined with a stock that has already given back nearly 8% on the month, suggests the market is not positioned for a clean beat.

The Street remains constructive but is not a large, diversified voice. Analyst coverage is concentrated, with Jones Trading the most active firm, maintaining a Buy and a $40 target in early October. Northland Capital Markets echoed Outperform at $40 in June after lifting from $30. Against a current price of $28.52, the mean target of $39 implies roughly 37% implied upside, though the coverage base is narrow and much of the bullish case rests on the same federal policy thesis. The bull argument is specific: roughly 6,000 idle beds that could generate over $300 million in annualized revenue once activated, plus Florida Department of Corrections contracts worth around $100 million annually. Bears point to NOI margin compression, now at 25.8% versus 27.2% a year ago, and funding access constraints tied to ESG-linked lender scrutiny. On valuation, GEO trades at a PE of 17.3 and EV/EBITDA of 8.9, both of which have edged higher on the week but sit meaningfully below year-ago levels on the 30-day PE move of negative 1.6 turns. The EPS surprise factor score ranks in the 84th percentile, a useful reminder that GEO has consistently beaten estimates even when sentiment has been cautious.

One data point stands apart from the rest this week. The ORTEX Alt Data layer shows Wikipedia page-view attention for GEO registering a z-score of 6.7 against its own prior 90-day history as of October 22. That is an unusually large reading, indicating retail attention has surged well above recent norms. This is a measure of attention, not a revenue or earnings signal, and no alt data dataset for GEO has been measured to lead its financial figures. But the attention spike coincides with a week of above-average volume and the PCR uptick, and it places GEO in a category of names that retail traders are watching actively into a print.

Open-market insider selling has been a quiet headwind in the background. Three insiders sold shares between mid-August and mid-September at prices between $31.31 and $32.00, totalling around $911,000 in proceeds. None were under a 10b5-1 plan, making these discretionary sales. Net insider activity over the 90 days to mid-September came to negative 32,300 shares and negative $1.02 million in value. None of the sellers were CEO or CFO, and the amounts are not large relative to the company's float, but the absence of any open-market buying from insiders in recent months is a mild signal worth carrying into the earnings read.

The next focus point is the November 5 release, where the key question is whether activated bed capacity and Florida contract contributions have shown up in the revenue line, and whether margins have stabilised after two consecutive quarters of compression.